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[57] ABSTRACT 
The present invention includes a poly(vinyl alcohol) hydro-
gel construct having a wide range of mechanical strengths 
for use as a human tissue replacement. A process in con-
nection with the present invention eliminates any step 
involved with dehydration of the hydrogel prior to implan-
tation thereof. The hydrogel construct may include a tissue 
scaffolding, a load bearing surface within a joint, or any 
other structure which is suitable for supporting the growth of 
tissue. 






time and capital expense associated with machinery which 
must accomplish the dehydration step. Additionally, dehy-
dration may denature bioagents included in the hydrogel. 
With the foregoing disadvantages of the prior art in mind, This application claims priority to provisional application 
Ser. No. 60/045,875, filed on May 5, 1997, which is incor-
porated herein by reference in its entirety. 
FIELD OF THE INVENTION 
5 it is an object of the present invention to provide a biocom-
patible PVA hydrogel which includes a mechanical strength 
range sufficient for a wide variety of applications as bioma-
terial. 
The present invention relates generally to hydrogel bio-
materials for use as tissue replacements or scaffolds. More 
specifically, the present invention relates to a poly(vinyl 
alcohol) ("PVA") cryogel for use as a structural member or 
as a tissue scaffolding in vivo. 
It is another object of the present invention to provide a 
10 method for producing the PVA hydrogel which precisely 
controls the mechanical strength thereof, and which elimi-
nates any dehydration step prior to implantation. 
DESCRIPTION OF THE PRIOR ART 
Other objects, features and advantages of the present 
invention will become apparent upon reading the following 
15 
specification. 
Most tissues of the living body include a large weight 
percentage of water. Therefore, in a selection of a prosthesis, 
a hydrous polymer (hydrogel) is considered to be superior in 
biocompatibility as compared to nonhydrous polymers. 20 
Although hydrogels do less damage to tissues than nonhy-
drous polymers, conventional hydrogels have historically 
included a serious defect in that they are inferior in mechani-
cal strength. For that reason, the use of hydrogels has been 
extremely limited in the past. 25 
Artisans have proposed a number of hardening means for 
improving mechanical strength. Some hardening means 
include treating the hydrogel with a cross-linking agent such 
as formaldehyde, ethylaldehyde, glutaraldehyde, tereph- 30 
thalaldehyde or hexamethylenediamine. Unfortunately, 
however, it is well known that those treatments decrease the 
biocompatibility of the hydrogel biomaterial. One example 
SUMMARY OF THE INVENTION 
Generally speaking, the present invention relates to a 
novel poly(vinyl alcohol) ("PVA") cryogel tissue replace-
ment construct and a process for making the construct. 
More specifically, the present invention relates to a non-
dehydrated PVAcryogel construct which is capable of being 
molded into a number of shapes, and which is capable of 
retaining a wide range of mechanical strengths for various 
applications. The PVA cryogel may comprise a PVA poly-
mer starting material in the form a dry powder wherein the 
degree polymerization of the PVA may range approximately 
500 to 3,500. The tissue replacement in accordance with the 
present invention may include approximately 2 to approxi-
mately 40 parts by weight PVA and approximately 98 to 60 
parts by weight water. Additionally, the hydrogel may 
include an isotonic saline solution substitute for water to 
prevent osmotic imbalances between the tissue replacement of a popular hydrogel which has been proposed for use as a 
biomaterial is PVA. 35 and surrounding tissues. The replacement may also include 
a number of bioactive agents including, but not limited to, 
heparin, growth factors, collagen cross-linking inhibitors 
such as ~-aminopropeonitrile (~APN), matrix inhibitors, 
antibodies, cytokines, integrins, thrombins, thrombin 
Numerous references generally describe the process of 
freezing and thawing PVA to create a hydrogel: Chu et al., 
Poly(vinyl alcohol) Cryogel: An Ideal Phantom Material for 
MR Studies of Arterial Elasticity, Magnetic Resonance in 
Medicine, v. 37, pp. 314-319 (1997); Stauffer et al., Poly 
(vinyl alcohol) hydrogels prepared by freezing-thawing 
cyclic processing, Polymer, v.33, pp. 3932-3936 (1992); 
Lozinsky et al., Study of Cryostructurization of polymer 
systems, Colloid & Polymer Science, v. 264, pp. 19-24 
(1986); Watase, Thermal and rheological properties of poly 45 (vinyl alcohol) hydrogels prepared by repeated cycles of 
freezing and thawing, Makromol. Chem., v. 189, pp. 
871-880 (1988). The disclosure from these references is 
hereby incorporated by reference. 
40 inhibitors, proteases, anticoagulants and glycosaminogly-
Another such reference is U.S. Pat. No. 4,734,097, issued 50 
to Tanabe, et al. on Mar. 29, 1988 ("Tanabe"). Tanabe 
proposes the construct of a molded hydrogel obtained by 
pouring an aqueous solution containing not less than 6% by 
weight of a polyvinyl alcohol which has a degree of hydroly-
sis not less than 97 mole percent and an average polymer- 55 
ization degree of not less than 1,100 into a desired shape of 
a vessel or mold, freeze molding an aqueous solution in a 
temperature lower than minus 5° C., then partially dehy-
drating the resulting molded product without thawing it up 
to a percentage of dehydration not less than 5 weight 60 
percent, and if required, immersing the partially hydrated 
molded part into water to attain a water content thereof in the 
range of 45 to 95 weight percent. 
The disadvantage to Tanabe, et al. is that it necessarily 
requires a step of dehydration in preparing the PVA hydro- 65 
gel. There are several disadvantages associated with the 
dehydration step. First, the dehydration step adds additional 
cans. 
A process in accordance with the present invention 
involves mixing water with the PVA crystal to obtain a 
non-dehydrated PVA hydrogel, thereby eliminating the 
dehydration step prior to implantation. More specifically, the 
present invention involves freezing and thawing the PVN 
water mixture to create an interlocking mesh between PVA 
polymer molecules to create the PVA cryogel. The freezing 
and thawing step may be performed at least twice, with 
mechanical strength of the PVA cryogel increasing each time 
the freezing and thawing step is performed. The process may 
include the further steps of pouring the PVNwater mixture 
into a mold, freezing the mixture, and the thawing the 
mixture to obtain a non-dehydrated construct. Additionally, 
the process may also include the step of removing the 
construct from the mold, immersing the construct in water, 
freezing the construct while immersed in water and thawing 
the construct while immersed in water to increase the 
mechanical strength of the construct. The process may also 
include the steps of adding bioactive agents to the hydrogel. 
Because it can be manufactured to be mechanically 
strong, or to possess various levels of strength among other 
physical properties, it can be adapted for use in many 
applications. The cryogel also has a high water content 
which provides desirable properties in numerous applica-
tions. For example, the cryogel tissue replacement construct 
is especially useful in surgical and other medical applica-
5,981,826 
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stiffness are desirable. Poly(vinyl alcohol) having an aver-
age molecular weight of from about 11,000 to 500,000 is 
preferred for practicing the invention. Poly(vinyl alcohol) 
having an average molecular weight of from about 85,000 to 
5 186,000 is even more preferred for practicing the invention, 
especially when producing vascular grafts, and poly(vinyl 
alcohol) having an average molecular weight of from about 
124,000 to 186,000 is especially preferred. 
tions as an artificial material for replacing and reconstructing 
soft tissues in humans and other mammals. Soft tissue body 
parts which can be replaced or reconstructed by the cryogel 
include, but are not limited to, vascular grafts, heart valves, 
esophageal tissue, skin, corneal tissue, cartilage, meniscus, 
and tendon. Furthermore, the cryogel may also serve as a 
cartilage replacement for anatomical structures including, 
but not limited to an ear or nose. The inventive cryogel may 
also serve as a tissue expander. Additionally, the inventive 
cryogel may be suitable for an implantable drug delivery 10 
device. In that application, the rate of drug delivery to tissue 
will depend upon cryogel pore size and degree of intermo-
lecular meshing resulting from the freeze/thaw device. The 
rate of drug delivery increases with the number of pores and 
decreases with an increasing degree of intermolecular mesh- 15 
ing from an increased number of freeze/thaw cycles. 
The cryogel is especially suitable for vascular grafts and 
heart valve replacements, because the cryogel is 
thromboresistant, and because of the particular mechanical 
and physiological requirements of vascular grafts when 
implanted into the body. The cryogel may also be used for 
contact lenses, as a covering for wounds such as burns and 
abrasions, and in other applications wherein a mechanically 
strong material is preferred. 
Other objects, features and advantages of the present 
invention will become apparent upon reading the following 
specification, when taken in conjunction with the accompa-
nying examples. 
The average degree of polymerization for preferred poly 
(vinyl alcohol)s generally ranges from about 500 to 3500, 
and poly(vinyl alcohol) having a degree of polymerization 
of from about 2700 to 3500 is especially preferred. Preferred 
poly(vinyl alcohol) typically has a degree of saponification 
(or hydrolysis) in excess of 80%, more preferred poly(vinyl 
alcohol) is saponified (or hydrolyzed) in excess of about 
97%, and even more preferred poly(vinyl alcohol) is saponi-
fied (or hydrolyzed) in excess of 99%. High molecular 
weight poly(vinyl alcohol) in crystal form, available from 
the Aldrich Chemical Company, is a good example of a 
20 poly( vinyl alcohol) suitable for practicing the present inven-
tion. 
The water that is mixed with the poly(vinyl alcohol) is 
preferably deionized and ultra filtered to minimize the 
potential for any contamination of the poly(vinyl alcohol). 
25 The mixture is preferably prepared by mixing from about 2 
to about 40 parts by weight poly(vinyl alcohol) with about 
98 to 60 parts by weight water. The concentration of the 
poly(vinyl alcohol) contributes to the stiffness of the 
Reference will now be made in detail to the description of 30 
the invention. While the invention will be described in 
cryogel, and can thus be chosen depending upon the stiffness 
of the material one desires to obtain. A more preferable 
connection with specific examples, there is no intent to limit 
it to the embodiment or embodiments disclosed therein. On 
the contrary, the intent is to cover all alternatives, modifi-
cations and equivalents included within the spirit and scope 
of the invention as defined by the appended claims. 
DETAILED DESCRIPTION OF IBE 
PREFERRED EMBODIMENTS 
In a preferred embodiment, a process in accordance with 
the present invention produces the cryogel in a two stage 
process. In the first stage a mixture of poly(vinyl alcohol) 
and water is placed in a mold, and repeatedly frozen and 
thawed, in cycles, until a suitable cryogel is obtained. In a 
second stage, the cryogel is removed from the mold, placed 
in water, and undergoes at least one other freeze-thaw cycle 
until desirable mechanical properties are achieved. In the 
first stage, a series of sequential steps is employed compris-
ing: (i) mixing water with poly(vinyl alcohol) to obtain a 
poly(vinyl alcohol)/water mixture; (ii) freezing the mixture; 
(iii) thawing the mixture; and (iv) repeating the freeze and 
thaw steps, as necessary, until a poly(vinyl alcohol) cryogel 
having the desired physical properties is obtained. If 
necessary, the second stage may then be employed. 
mixture is obtained by mixing from about 10 to about 20 
parts poly(vinyl alcohol) with from about 80 to about 90 
parts by weight water, and an especially preferred mixture is 
obtained by mixing about 15 parts poly(vinyl alcohol) with 
35 
about 85 parts by weight water. Isotonic saline (0.9% by 
weight NaCl, 99.1 % water) or an isotonic buffered saline 
may be substituted for water to prevent osmotic imbalances 
between the material and surrounding tissues if the cryogel 
is to be used as a soft tissue replacement. 
40 
After the poly(vinyl alcohol) and water are mixed, it is 
often necessary to process the mixture to ensure that the 
poly(vinyl alcohol) is adequately solubilized. Suitable solu-
bilization processes are generally known in the art and 
45 include, for example, heating the mixture, altering the pH of 
the mixture, adding a solvent to the mixture, subjecting the 
mixture to external pressure, or a combination of these 
processes. A preferred method is to heat the mixture in an 
autoclave, at a temperature of about 120° C., and a pressure 
50 of about 17 p.s.i., for about 25 minutes, is typically effective 
to solubilize the poly(vinyl alcohol) and, in addition, to 
sterilize the mixture before further processing. 
Poly(vinyl alcohol) useful for the invention is typically 55 
obtained as a dry powder or crystal, and can vary based upon 
several factors, including morlecular weight, degree of 
polymerization, and degree of saponification (or hydrolysis). 
The molecular weight of the poly(vinyl alcohol) can vary, 
and can be chosen depending upon the particular application 60 
envisioned for the cryogel. Generally, increasing the 
molecular weight of the poly(vinyl alcohol) increases the 
tensile strength and tensile stiffness, and thereby improves 
the properties of constructs such as vascular grafts, wherein 
increased strength is desirable. In other applications, such as 65 
cartilage, lower molecular weight poly( vinyl alcohol) can be 
employed because lower tensile strength and lower tensile 
After the mixture has been prepared, air bubbles that may 
have become entrapped in the mixture should be removed. 
The solution can be allowed to sit for a period of time, 
preferably at an elevated temperature, to allow the air 
bubbles to rise out of solution. The mixture can also be 
placed in a sterile vacuum chamber for a short time to bring 
the bubbles out of solution. 
Once prepared, the mixture can be poured into one or 
more pre-sterilized molds. If needed, the solution in the 
mold can be allowed to sit upright, or subjected to a vacuum 
in a vacuum chamber, to remove undesirable air bubbles. 
The shape and size of the mold may be selected to obtain a 
cryogel of any desired size and shape. Vascular grafts, for 
example, can be produced by pouring the poly(vinyl 
alcohol)/water mixture into an annular mold. The size and 
5,981,826 
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dimensions of the mold can be selected based upon the 
location for the graft in the body, which can be matched to 
physiological conditions using normal tables incorporating 
limb girth, activity level, and history of ischemia. Suitable 
annular molds for producing vascular grafts would include 5 
Y-shaped molds, which can be used to produce grafts having 
vascular branching. The cryogel can also be processed by 
cutting or otherwise forming the cryogel into the desired 
form after it has been produced. Although not necessary, 
molds are preferably capped or sealed to prevent dehydra- 10 
tion and to preserve sterility. Typically, the mold is not filled 
entirely with the solution in order to accommodate for the 
expansion during freezing that occurs when freezing water. 
Molds for practicing the invention can be comprised of 
many suitable materials that will not react with the poly 15 (vinyl alcohol) solution, that will maintain integrity over the 
required, temperature range, and that will allow the cryogel 
6 
vascular graft applications especially, more preferably from 
about 2 to about 5 times. Most preferably, the freeze/thaw 
cycle is repeated twice, for a total of three freeze/thaw cycles 
in the first stage. 
After the material has undergone the first stage of freeze/ 
thaw treatment it is carefully removed from the mold in 
order to avoid damaging the material, and immediately 
submerged in a liquid bath, preferably of deionized, sterile 
water. The material can be removed from the mold in either 
thawed or frozen state. Moreover, the material can be 
removed from either part or the entire mold. For example, it 
may be suitable to retain the mandrels within the material if 
an annular mold is employed, to prevent the material from 
deforming. The bath should be large enough so that the 
material is immersed completely in water, and can be open 
or closed, but preferably closed to maintain sterility. 
The second stage involves further freeze/thaw treatment 
of the molded material. After the mixture is immersed in 
water, it is again subjected to one or more freeze/thaw cycles 
in the second stage of the processing. Again, the conditions 
for each freeze/thaw cycle in the second stage need not be 
identical. The mixture should preferably be frozen and 
thawed from about 1 to about 15 times, more preferably, 
especially for vascular graft applications, from 1 to 3 times, 
and most preferably twice, while the mixture is submerged 
in the water. As in the first stage, increasing the number of 
freeze/thaw cycles increases the tensile strength and tensile 
stiffness, and the number of cycles can thus be selected 
based upon the particular application that is planned for the 
cryogel. 
to be removed without damaging the cryogel. Suitable 
materials include but are not limited to natural and synthetic 
resins, natural and synthetic polymers (including those 20 
based upon polycarbonates, acrylates and methacrylates, 
and poly(vinyl alcohol)), glass, steel, aluminum, brass, and 
copper, among other materials. Outer molds that are com-
pliant and elastic result in a more complete gelling and better 
physical properties than molds that are stiff. High pressure 25 
in the frozen poly(vinyl alcohol) reduces the stiffness of the 
resulting gel, and compliant molds reduce the pressure on 
the poly(vinyl alcohol) while it is frozen. Preferred annular 
molds are constructed from smooth stainless steel or poly 
(vinyl chloride) tubes around stainless steel mandrels. More 30 
preferred annular molds are constructed of compliant poly 
(vinyl chloride) or other plastic tubes around stainless steel 
mandrels. 
The conditions under which the freeze/thaw cycles of the 
second stage are carried out are generally comparable to the 
conditions observed in carrying out the first stage. After the 
35 mixture has undergone the second stage of freeze/thaw 
cycles, it is ready for use. 
After the mixture has been poured into the mold, and the 
mold has been sealed, it is frozen to a temperature preferably 
below about -5° C., and more preferably below about -20° 
C. The mixture should preferably be frozen for at least 2 
hours, including freezing time, more preferably at least 4 
hours, and most preferably from about 4 to about 16 hours. 
In contrast to methods recited in the prior art, no dehydration 
step is required, and in a preferred embodiment dehydration 
is not employed because of the importance of hydration to 
the final product. 
After the mixture has been frozen, the temperature of the 
mixture is raised and the mixture thawed. It is generally 
preferable to raise the temperature to from about 5 to about 
55° C., and to thaw the solution at such temperature for a 
period of time of about 2 hours or more, and more preferably 
at least 4 hours, and most preferably from about 4 to about 
16 hours, including thawing time and time at such tempera-
ture. It is especially preferable to raise the temperature to 
about 22° C., and to thaw the mixture at such temperature for 
about 12 hours. Because the hydrogel is solubilized at higher 
temperatures, the temperature of the mixture should not 
generally be raised above about 60° C. 
After the mixture has been frozen and thawed once under 
the foregoing conditions, the process may be repeated, 
although the exact process conditions need not be repeated 
for each freeze/thaw cycle. Generally, increasing the number 
The poly(vinyl alcohol) cryogel of the present invention 
can also comprise a bioactive agent to lend to the cryogel 
suitable physiological properties for it to be used as a soft 
40 tissue replacement. The bioactive agent can be chosen based 
upon the particular application planned for the replacement, 
and the particular physiological properties required of the 
replacement in the application involved. Many such bioac-
tive agents would be released gradually from the cryogel 
45 after implantation, and thereby delivered in vivo at a 
controlled, gradual rate. The cryogel can thus act as a drug 
delivery vehicle. Other bioactive agents can be incorporated 
in to the cryogel in order to support cellular growth and 
proliferation on the surface of the material. Bioactive agents 
50 which can be included in the replacement include, for 
example, growth factors, collagen crosslinking inhibitors 
such as ~-aminopropeonitrile (~APN) or cis-4-hydroxy-
proline, matrix inhibitors, antibodies, cytokines, integrins, 
thrombins, thrombin inhibitors, proteases, anticoagulants, 
55 and glycosaminoglycans. Heparins are particularly suitable 
agents for incorporating into vascular grafts, because of their 
anticoagulant properties, and thus their ability to inhibit 
thrombosis on the surface of the cryogel. 
of freeze/thaw cycles increases the tensile strength and 60 
tensile stiffness of the cryogel, and can be implemented for 
applications such as vascular grafts wherein higher strength 
and stiffness are desired. In other applications, such as 
cartilage, lower numbers of freeze/thaw cycles can be 
employed because lower tensile strength and lower tensile 65 
stiffness are desirable. It is generally preferred to repeat the 
freeze/thaw cycle from about 0 to about 15 times, and, in 
In order to embed heparin or other bioactive agents into 
the cryogel of the present invention any of a pre-sterilized 
heparin powder, aqueous heparin or aqueous heparin sus-
pension can be mixed into the starting sterile poly(vinyl 
alcohol)/water mixture. After the heparin or other bioactive 
agent is incorporated into the poly(vinyl alcohol)/water 
mixture, it is thermally processed along with the poly(vinyl 
alcohol)/water mixture according to the process described 
herein. Heparin and other bioactive agents can also be 
5,981,826 
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introduced into the cryogel by placing the cryogel into a bath 
containing an aqueous solution of the agent and allowing the 
agent to diffuse into the cryogel. 
The concentration of the heparin or other bioactive agent 
8 
(124,000-186,000 Av. MW), 99+% saponification, available 
for Aldrich Chemical Company, in 100 ml. of deionized, 
sterile water. The mixture was placed in a loosely capped 
in the mixture may be selected for the particular application 5 
involved. For heparin incorporation into a vascular graft, 
concentrations will typically range from 1 unit/ml. to 1,000, 
000 units/ml. Lower concentrations will be employed to 
inhibit coagulation on the graft surface, and higher concen-
trations will be used where local infusion of heparin into the 10 
blood is desired to inhibit thrombosis downstream of the 
graft, as described in Chen et al., Boundary layer infusion of 
heparin prevents thrombosis and reduces neointimal hyper-
plasia in venous polytetrafiuoroethylene grafts without sys-
temic anticoagulation, J. Vascular Surgery, v. 22, pp., 15 
237-247 (1995). 
container, heated and sterilized at 120° C. and 17 p.s.i. in an 
autoclave for about 25 minutes. The container was then 
sealed removed from the autoclave and placed under a 
sterile ventilation hood. The mixture was then stirred to 
ensure a homogenous solution. The mixture was poured into 
sterile syringes, being careful not to generate air bubbles. 
The poly( vinyl alcohol) solution was then injected upwardly 
into stainless steel annular molds having stainlesssteel man-
drels. The outer tube of the annulus had an inner diameter of 
8 mm. which surrounded a 5 mm. diameter mandrel. The 
time that the solution was exposed to air was minimized in 
order to prevent evaporation of water. The mold was 
designed to create a poly(vinyl alcohol) cryogel with 
approximately a 1.5 mm. wall thickness, 10 cm. long, having 
a 5 mm. inside diameter. The mold was sealed at both ends 
using 0-rings and rubber caps. Air space, equaling about 8% 
The cryogel supports the proliferation of eukaryotic cell 
cultures. Vascular cells such as endothelial cells smooth 
muscle cells, and fibroblasts and other connecti~e tissue 
cells, can thus be incorporated into the cryogel. Human 
aortic endothelial cells and human dermal fibroblasts are 
also compatible with the cryogels of the present invention. 
Cryogels modified by such cell lines are, in turn, especially 
well adapted for implantation into the human body, and for 
use as soft tissue replacement parts in the human body. 
Indeed, replacement parts modified by such cell lines are 
better able to adapt and adjust to changing physical and 
physiological conditions in the body, and thereby to prevent 
any failure of the cryogel which might otherwise occur. 
Cryogels modified by such cell lines are, in sum, especially 
well adapted for implantation in the human body, and for use 
as replacement parts in the human body. These cellular lines 
can be incorporated into the cryogel, after it has been 
produced via standard in-culture protocol generally known 
in the art. It is especially effective to culture human aortic 
endothelial cells and human dermal fibroblasts using direct 
topical seeding and incubation in cell culture medium. 
Besides the soft tissue replacement uses set forth for the 
poly( vinyl alcohol) cryogel, discussed above, the cryogels of 
the present invention can be used in any application in which 
poly(vinyl alcohol) cryogels are generally suitable, includ-
ing as an MR (magnetic resonance) quality control phantom, 
as an ultrasound or radio frequency thermal therapy trans-
mission pad, as a substitute for an ice bag, as a denture base, 
and in other medical applications. 
Although the following examples set out specific param-
eters for constructing a PVAhydrogel in accordance with the 
present invention, the ordinarily skilled artisan will under-
stand that mechanical properties of the PVA hydrogel may 
be affected by one of four factors. Those factors include: (1) 
weight percentage of the respective constituents within the 
hydrogel (e.g. PVA polymer and water); (2) the molecular 
weight of the PVA starting material; (3) the number of 
freeze/thaw cycles; and (4) the duration of a freeze cycle. It 
is also important to note that the freeze/thaw cycle promotes 
an interlocking mesh or entanglement between molecules of 
PVA to create the mechanical strength. This is different than 
the traditional cross link accomplished by the above-
referenced cross linking agents which inevitably introduces 
a toxic agent into the biomaterial, thus decreasing biocom-
patibility of materials which utilize those cross linking 
agents. 
EXAMPLE 1 
A 15% by weight poly(vinyl alcohol) solution was pre-
pared by mixing 17.6 grams of poly(vinyl alcohol) polymer 
20 of the volume of the mold was deliberately maintained in 
order to allow for expansion while the aqueous solution 
froze. 
The tube was then subjected to three (3) cycles of freezing 
and thawing. In each of the cycle the tube was frozen by 
25 placing it upright in a commercial freezer regulated at about 
-20° C., and allowing it to air cool for about 12 hours. The 
tube was then thawed by removing the tube from the freezer 
and setting it upright under ambient conditions. The tube 
was allowed to thaw for about 12 hours before being 
30 returned to the freezer for another cycle. 
After the mixture had been frozen and thawed three times 
it was removed from the tube (under a sterile vacuum hood) 
and immersed in a 50 ml, centrifuge vial containing 35 ml. 
of deionized, sterile water. There was obtained a translucent 
35 to clear, gummy, weak material which was substantially 
unable to maintain its shape outside of water or other liquid. 
The material was handled carefully with forceps and 
immersed in water as quickly as possible. The inner diam-
eter of the material was preserved by keeping the mandrel in 
40 place. The container was then sealed and placed in a freezer 
at about -20° C. The mixture was kept in the freezer for 
about 12 hours, and then removed and allowed to stand at 
room temperature for about 12 hours. The freezing and 
thawing process was repeated once thus, considering the 
45 three previous cycles within the mold, the mixture was 
subjected to a total of five (5) cycles of freezing and thawing. 
The material obtained was opaque, elastic, and non-
sticky, with mechanical properties very similar to a native 
artery tissue. The material was tested for mechanical 
50 strength according to standards of the Association for the 
Advancement of medical Instrumentation and the American 
National Standards Institute, published in Cardiovascular 
implants-Vascular Prosthesis, ANSl/AAMI VP20-1994, 
section 8.3.3.3 (pressurized burst strength), and section 8.8 
55 (suture retention strength). The material had a burst pressure 
of about 540 mm Hg. Specifically, a 6-0 suture was placed 
2 mm from the edge of the graft and pulled at a rate of 150 
mm/min until it pulled through the graft. The average peak 
pullout load for the material a suture test was about 289 
60 grams, which is greater than the pullout loads reported in the 
literature for human artery and vein. Finally, the tensile 
modulus of elasticity of the material was measured to be 
approximately 4.0x105 Pa 
65 EXAMPLE 2 
A 30% by weight poly(vinyl alcohol) solution was pre-
pared by mixing poly(vinyl alcohol) polymer (124,000-186, 
5,981,826 
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The cryogel is especially suitable for vascular grafts and 
heart valve replacements, because the cryogel is 
thromboresistant, and because of the particular mechanical 
and physiological requirements of vascular grafts when 
implanted into the body. The cryogel may also be used for 
contact lenses, as a covering for wounds such as burns and 
abrasions, and in other applications wherein a mechanically 
strong material is preferred. 
Throughout this application, various publications are ref-
erenced. The disclosures of these publications in their entire-
ties are hereby incorporated by reference into this applica-
tion in order to more fully describe the state of the art to 
which this invention pertains. 
The foregoing description has been presented for pur-
000 Av. MW), 99+% saponification, in deionized, sterile 
water. As with Example 1, the mixture was placed in a 
loosely capped container, heated, sealed removed from the 
autoclave, placed under a sterile ventilation hood, stirred to 
ensure a homogenous solution, poured into sterile syringes, 5 
and injected into the molds according to the process of 
Example 1. In this example, however, the tube was then 
subjected to ten (10) cycles of freezing and thawing. The 
freeze/thaw cycles were similar to that of Example 1, except 
that the sample was allowed to cool for about 24 hours for 10 
each freeze/thaw cycle. The tube was then thawed by 
removing the tube from the freezer and setting it upright 
under ambient conditions. The tube was allowed to thaw for 
about 12 hours before being returned to the freezer for 
another cycle. The resulting PVA biomaterial was stiff and 
strong with a burst pressure of approximately 1078 mm Hg. 
15 poses of illustration and description. It is not intended to be 
exhaustive or to limit the invention to the precise examples 
or embodiments disclosed. Obvious modifications or varia-
tions are possible in light of the above teachings. The 
embodiment or embodiments discussed were chosen and 
described to provide the best illustration of the principles of 
EXAMPLE 3 
20 the invention and its practical application to thereby enable 
one of ordinary skill in the art to utilize the invention in 
various embodiments and with various modifications as are 
suited to the particular use contemplated. All such modifi-
cations and variations are within the scope of the invention 
A 15% by weight poly(vinyl alcohol) solution was pre-
pared by mixing poly(vinyl alcohol) polymer (89,000-98, 
000 Av. MW), 99+% saponification, in deionized, sterile 
water in a manner substantially identical with Example 1 
except for the following differences. As with Example 1, the 
mixture was placed in a loosely capped container, heated, 
sealed removed from the autoclave, placed under a sterile 
ventilation hood, stirred to ensure a homogenous solution, 
poured into sterile syringes, and injected into the molds 
according to the process of Example 1. In this example, 
however, the tube was then subjected to five (5) cycles of 
freezing and thawing. The freeze/thaw cycles were similar to 30 
that of Example 1, in that each sample was allowed to cool 
for about 12 hours for each freeze/thaw cycle. The resulting 
PVA biomaterial was soft with a burst pressure of approxi-
mately 98 mm Hg. 
25 as determined by the appended claims when interpreted in 
accordance with the breadth to which they are fairly and 
legally entitled. 
As demonstrated by the above-referenced examples, 35 
because the PVA cryogel can be manufactured to be 
mechanically strong, or to possess various levels of strength 
among other physical properties depending upon the weight 
percentage of the PVA starting material with respect to other 
constituents in solution, freeze time, the number of freeze/ 40 
thaw cycles, and the freeze temperature. As discussed above, 
the end product cryogel also has a high water content which 
provides desirable properties in numerous applications and 
which prevents the denaturing of additives. 
What is claimed is: 
1. A process for preparing a PVA construct comprising the 
steps of: 
pouring an aqueous PVA polymer mixture into a mold; 
freezing and thawing said PVA polymer mixture within 
said mold at least once to create an interlocking mesh 
between PVA polymer molecules to create the PVA 
cryogel; 
removing, at least partially, said PVA cryogel from said 
mold; 
immersing said PVA cryogel in an aqueous solution; and 
freezing and thawing said PVAcryogel at least once while 
immersed in water. 
2. The process of claim 1, comprising the further step, 
before immersing said PVA cryogel in water, of: 
removing, at least partially, said PVA cryogel from said 
mold. 
3. The process of claim 1, wherein said aqueous PVA 
polymer mixture comprises a PVA polymer starting material 
having a molecular weight ranging from approximately 
11,000 to approximately 500,000. 
4. The process of claim 1, wherein said aqueous PVA 
polymer mixture is biocompatible and comprises a PVA 
polymer starting material in the form of a dry powder. 
5. The process of claim 1, wherein said aqueous PVA 
polymer mixture comprises a PVA starting material in the 
form of a dry powder, and further wherein a degree of 
polymerization of the PVA starting material ranges from 
approximately 500 to approximately 3500. 
The cryogel tissue replacement construct is especially 45 
useful in surgical and other medical applications as an 
artificial material for replacing and reconstructing soft tis-
sues in humans and other mammals. Soft tissue body parts 
which can be replaced or reconstructed by the cryogel 
include, but are not limited to, vascular grafts, heart valves, 50 
esophageal tissue, skin, corneal tissue, cartilage, meniscus, 
and tendon. The cryogel may be formed as an implantable 
articulating surface for a load bearing joint, whereby the 
articulating surface may be fixed to bone with screws, 
sutures, or bioglue such as a collagen glue. Furthermore, the 55 
cryogel may also serve as a cartilage replacement for ana-
tomical structures including, but not limited to an ear or 
nose. 6. The process of claim 1, wherein said aqueous PVA 
polymer mixture comprises a PVA starting material in the 
60 form of a dry powder with a degree of hydrolysis in excess 
of approximately 80 percent. 
The inventive cryogel may also serve as a tissue expander. 
Additionally, the inventive cryogel may be suitable for an 
implantable drug delivery device. In that application, the 
rate of drug delivery to tissue will depend upon cryogel pore 
size and degree of intermolecular meshing resulting from the 
freeze/thaw cycles. The rate of drug delivery increases with 
the number of pores and decreases with an increasing degree 
of intermolecular meshing from an increased number of 
freeze/thaw cycles. 
7. The process of claim 1, wherein said aqueous PVA 
polymer mixture comprises a PVA starting material in the 
form of a dry powder with a degree of hydrolysis in excess 
65 of approximately 99 percent. 
8. The process of claim 1, wherein said aqueous PVA 
polymer mixture comprises approximately 2 to approxi-
5,981,826 
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mately 40 parts by weight PVA and approximately 98 to 
approximately 60 parts by weight water. 
9. The process of claim 1, wherein said aqueous PVA 
polymer mixture comprises approximately 20 to approxi-
mately 40 parts by weight PVA and approximately 60 to s 
approximately 80 parts by weight water. 
12 
17. The product of claim 16 wherein said tissue scaffold 
has an open-celled structure for promoting tissue ingrowth. 
18. The product of claim 1 comprising a tissue expander. 
19. The product of claim 1 comprising an implantable 
articulating surface for a load bearing joint. 
20. The product of claim 19 wherein the articulating 
surface is fixed to bone with internal fixators comprising at 
least one of screws or sutures. 
10. The process of claim 1, wherein said aqueous PVA 
polymer mixture comprises an isotonic saline solution to 
prevent osmotic imbalances between the tissue replacement 
and surrounding tissues. 
11. The process of claim 10, wherein said isotonic saline 
solution comprises approximately 0.9 percent NaCl and 
approximately 99.1 percent water. 
21. The product of claim 19 wherein the articulating 
10 surface is arranged and configured to be fixed to bone with 
a glue. 
12. The product according to the process of claim 1. 
13. The product of claim 12, further comprising a bioac- 15 
tive agent. 
14. The product of claim 13, wherein said bioactive agent 
is selected from the group consisting of: a heparin, a ~APN, 
an antibody, a cytokine, an integrin, a protease, a matrix 
inhibitor, an anticoagulant, a sphyngolipid, a thrombin, a 20 
thrombin inhibitor, and a glycosaminoglycan. 
15. The product of claim 1 comprising a tissue replace-
ment. 
16. The product of claim 1 comprising a tissue scaffold. 
22. The product of claim 21 wherein the glue comprises 
a collagen glue. 
23. The product of claim 1 comprising a cartilage replace-
ment. 
24. The product according to the process of claim 2. 
25. The product according to the process of claim 3. 
26. The product according to the process of claim 4. 
27. The product according to the process of claim 5. 
28. The product according to the process of claim 6. 
29. The product according to the process of claim 8. 
30. The product according to the process of claim 10. 
* * * * * 
